TELO | Jotup

Telomir Pharmaceuticals’ Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024

Retrieved on:

Tuesday, April 2, 2024

Press club, B cell, Longevity, TELO, Chromosome, Research, DNA, MD, Skin, Osteoarthritis, Blood, Ageing, Pharmaceutical industry

BALTIMORE, April 02, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to potentially address age-related conditions, today announced that anti-aging expert and New York Times bestselling author Michael F. Roizen, MD, will present promising pre-clinical research on Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024. Dr. Roizen serves as Telomir’s special advisor on age reversal.

Key Points:

Dr. Roizen serves as Telomir’s special advisor on age reversal.
The search for treatments to combat the diseases of aging has increasingly become the focus of many medical professionals and, more recently, society in general.
“Our event at the National Press Club will provide us with an opportunity to share Telomir-1’s potential with the public on a national stage,” stated Chris Chapman, MD, co-founder, chairman, chief executive officer and president of Telomir Pharmaceuticals.
As Telomir continues to uncover new and promising data through our pre-clinical work, we remain committed to sharing our data publicly.

Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

Retrieved on:

Friday, March 29, 2024

Diagnosis, B cell, Regeneration, TELO, Disease, Research, Nonsteroidal anti-inflammatory drug, MD, Quality of life, Human, Osteoarthritis, FDA, Ageing

BALTIMORE, March 26, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to potentially address age-related conditions, today announced that Telomir and global animal health research company Argenta have agreed to begin a three to six-months study on the efficacy of Telomir-1 as a treatment for osteoarthritis and other diseases of aging in canines.

Key Points:

The study will evaluate the efficacy of Telomir-1 for mitigating the progression of osteoarthritis based on symptomatic, radiographic, gross pathologic and histopathologic evaluations.
In addition, Telomir believes that this study could be used as part of its pre-clinicial program for eventually evaluating Telomir-1 in humans.
It is estimated that nearly 18 million canines in the United States are affected by osteoarthritis.
“Osteoarthritis is the most common ailment in canines yet there are currently no treatments that combat the disease.

Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th

Retrieved on:

Friday, March 22, 2024

BALTIMORE, March 22, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to potentially address age-related conditions, today announced that Telomir and Danielle R. Baker, Ph.D., of Frontage Laboratories will present a scientific poster presentation at the Global Longevity Federation Conference in Las Vegas on March 26th at 2 pm EDT. The poster will present new data regarding the effect of Telomir-1 on telomere length in three human cell lines.

Key Points:

The poster will present new data regarding the effect of Telomir-1 on telomere length in three human cell lines.
This presentation builds on the data that was presented at the National University Health System of Singapore (NUHS) Centre for Healthy Longevity Conference 2024 in February.
“Presenting our poster at the Global Longevity Federation conference offers a significant opportunity for our team to showcase the potential for Telomir-1.
To be added to the Telomir Pharmaceuticals email distribution list, please email [email protected] with TELO in the subject line.

Telomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidate’s Potential in DNA Age Reversal Science

Retrieved on:

Thursday, March 14, 2024

Toxicity, Notifiable disease, TELO, Entrepreneurship, Science, Research, DNA, Ageing, MD, Quality of life, Drug development, Osteoarthritis, Pharmaceutical industry

Telomir’s recent AI-powered research presented in Singapore last month not only supports but amplifies the therapeutic potential of Telomir-1.

Key Points:

Telomir’s recent AI-powered research presented in Singapore last month not only supports but amplifies the therapeutic potential of Telomir-1.
Additional AI-driven studies now being conducted to demonstrate Telomir-1's promising therapeutic potential, supporting Telomir’s hypothesis with solid computational evidence.
As part of its work, Telomir works with third-party collaborators Frontage Laboratories and InSilicoTrials, each of whom utilize AI in-silico testing models.
To be added to the Telomir Pharmaceuticals email distribution list, please email [email protected] with TELO in the subject line.

Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference

Retrieved on:

Thursday, March 7, 2024

Regeneration, AI, MD, Stem cell, Ageing, Drug development, National University Health System, Telomere, CHL, HUVEC, Conference, Longevity, B cell, NUHS, MSC, Poster, TELO, Research, Pharmaceutical industry

The data presented was garnered from pre-clinical studies that Telomir previously disclosed it was undertaking.

Key Points:

The data presented was garnered from pre-clinical studies that Telomir previously disclosed it was undertaking.
The data presented further demonstrated how Telomir-1 increases telomere length and its potential to successfully affect age-related inflammatory conditions.
The collaboration is expected to help accelerate the development of Telomir-1, improve its safety profile, and significantly reduce the research and development costs of Telomir’s drug development program.
To be added to the Telomir Pharmaceuticals email distribution list, please email [email protected] with TELO in the subject line.

Michael F. Roizen, MD to Increase Activities with Telomir Pharmaceuticals as Special Advisor on Age Reversal

Retrieved on:

Tuesday, March 5, 2024

BALTIMORE, March 05, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to affect age reversal, today announced that Michael F. Roizen, MD, a leader in age-related medicine and an existing advisor to the Company, will be increasing his role in the coming months as a Special Advisor on Age Reversal.

Key Points:

A board-certified internist and anesthesiologist, Dr. Roizen has been instrumental in the development of many successful ventures.
He also served 16 years on Food and Drug Administration (FDA) advisory committee and chaired one for two years.
Chris Chapman, MD, co-founder, chairman, chief executive officer and president of Telomir, stated, “Telomir's groundbreaking work has captured the attention and imagination of the industry.
We look forward to his continued contributions to our efforts.”
To be included in the Telomir Pharmaceuticals email distribution list, please email [email protected] with TELO in the subject line.

Telomir Pharmaceuticals Announces Closing of Initial Public Offering

Retrieved on:

Tuesday, February 13, 2024

Prospectus, Suite, Sale, Form, Brickell Avenue, IPO, TELO, Security (finance)

BALTIMORE, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to affect age reversal, today announced the closing of its initial public offering of 1,000,000 shares of common stock at a public offering price of $7.00 per share.

Key Points:

BALTIMORE, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to affect age reversal, today announced the closing of its initial public offering of 1,000,000 shares of common stock at a public offering price of $7.00 per share.
The gross proceeds to Telomir from the initial public offering were $7 million, before deducting underwriting discounts and commissions and other offering expenses.
Kingswood Investments, a division of Kingswood Capital Partners LLC, acted as sole book-running manager for the initial public offering.
333-275534) relating to shares of common stock sold in the initial public offering has been filed with the Securities and Exchange Commission (“SEC”) and was declared effective by the SEC on February 8, 2024.

Telomir Pharmaceuticals Announces Pricing of Initial Public Offering

Retrieved on:

Thursday, February 8, 2024

Suite, Sale, Form, IPO, TELO, Brickell Avenue, Prospectus, Security (finance)

In addition, Telomir has granted the underwriters a 45-day option to purchase up to an additional 150,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

Key Points:

In addition, Telomir has granted the underwriters a 45-day option to purchase up to an additional 150,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
The gross proceeds to Telomir from the initial public offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $7 million.
The initial public offering is expected to close on February 13, 2024, subject to satisfaction of customary closing conditions.
Kingswood Investments, a division of Kingswood Capital Partners LLC., is acting as sole book-running manager for the initial public offering.

New Electric Vehicle Manufacturer TELO Unveils the World’s Most Efficient EV Pickup Truck

Retrieved on:

Tuesday, June 13, 2023

TELO, a new electric vehicle manufacturer, officially unveiled the first-of-its-kind TELO Truck today.

Key Points:

TELO, a new electric vehicle manufacturer, officially unveiled the first-of-its-kind TELO Truck today.
TELO partnered with world-renown designer, advisor and investor Yves Béhar and Fuseproject for the vehicle design.
By redesigning the EV truck footprint and function from the ground up, TELO takes advantage of the best in electric and autonomous technology to meet the needs of both urban and suburban drivers.
The truck bed can also be modified to add a truck cap, where a third-row seat or a camping set-up can be placed.

Telo Genomics Announces Full-Services Investor Relations Agreement with Adelaide Capital

Retrieved on:

Tuesday, September 21, 2021

Toronto, Ontario--(Newsfile Corp. - September 21, 2021) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") is pleased to announce that it has entered into a consulting agreement (the "Consulting Agreement") with Adelaide Capital Markets Inc. ("Adelaide") to provide investor relations consulting services to the Company in compliance with the policies and guidelines of the TSX Venture Exchange (the "TSXV") and applicable legislation.

Key Points:

Toronto, Ontario--(Newsfile Corp. - September 21, 2021) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") is pleased to announce that it has entered into a consulting agreement (the "Consulting Agreement") with Adelaide Capital Markets Inc. ("Adelaide") to provide investor relations consulting services to the Company in compliance with the policies and guidelines of the TSX Venture Exchange (the "TSXV") and applicable legislation.
Adelaide will provide investor relations and consulting services to the Company, effective September 15, 2021.
Under the terms of the Consulting Agreement, Adelaide will receive C$8,000 per month from the Company for an initial period of 6 months (subject to extension by mutual agreement) until March 15, 2022.
Adelaide will, among other things, assist with investor introductions and communications, respond to investor and shareholder inquires, work with TELO to prepare corporate materials and press releases and coordinate non-deal roadshows, virtual campaigns, and conferences.